ECHO-202/KEYNOTE-037: Phase I/II Study of Epacadostat + Pembrolizumab in Pts With Advanced RCC

June 2-6, 2017; Chicago, Illinois
Epacadostat plus pembrolizumab safe, active in patients with advanced RCC with 47% ORR in patients who received ≤ 1 previous line of therapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 504 KB
Released: June 8, 2017


Supported by educational grants by
Celgene Corporation
Halozyme Therapeutics
Merck & Co., Inc.

Related Content

From Clinical Care Options (CCO), a video webinar on fundamentals of CAR T-cell therapy for pharmacy and managed care professionals

Craig Freyer, PharmD Zahra Mahmoudjafari, PharmD, BCOP, DPLA Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 24, 2021 Expired: September 23, 2022

Download this short slideset from Clinical Care Options (CCO) the use of androgen deprivation therapy for nonmetastatic or metastatic prostate cancer

Daniel W. Lin, MD Alicia K. Morgans, MD, MPH David F. Penson, MD Released: September 20, 2021

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

Eva M. Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 15, 2021

Slides from Clinical Care Options (CCO) on 2021 treatment recommendations for patients with nmCRPC.

David F. Penson, MD Released: September 10, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.